Literature DB >> 4074825

Testing for a trend in tumor prevalence rates: I. Nonlethal tumors.

G E Dinse.   

Abstract

In the analysis of animal carcinogenicity studies, the standard survival-adjusted test for a dose-related trend in the prevalence of nonlethal tumors is the Hoel-Walburg test, which stratifies on age at death by grouping survival times into intervals. An alternative analysis assesses trend on the basis of the likelihood score test under a logistic model for the prevalence function, which adjusts for survival by including age at death as a continuous regression variable. Extensive simulations demonstrate that the test based on modeling the prevalence log-odds as a linear function of age is more powerful than the Hoel-Walburg test, regardless of the intervals used by the latter to stratify the data. Without incorporating a continuity correction, the size of each test often exceeds the nominal level, especially when the mortality patterns differ across dose groups. Corrected versions of the tests operate at conservative levels, where the degree of conservatism varies with the distribution of the data. When the mortality patterns for the dose groups are similar, both tests have essentially the same power to detect a trend in tumor prevalence rates. However, when mortality varies with dose, the logistic regression test with a linear age term is more powerful than the Hoel-Walburg test, and this gain in power increases as the dose-specific mortality patterns become more disparate.

Entities:  

Mesh:

Year:  1985        PMID: 4074825

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  2 in total

1.  Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.

Authors:  D E Gunson; R E Steele; R Y Chau
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

2.  Linear mixed effects models under inequality constraints with applications.

Authors:  Laura Farnan; Anastasia Ivanova; Shyamal D Peddada
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.